Rep. Josh Gottheimer (D-NJ) Sells Abbott Laboratories (ABT) Stock

Representative Josh Gottheimer, a Democrat representing New Jersey's 5th District, recently disclosed a transaction involving Abbott Laboratories (ABT). According to a periodic transaction report, Gottheimer sold a stake in the healthcare company on May 27, 2026. The trade was valued in the range of $1,001 to $15,000 and was formally reported on June 4, 2026, in compliance with the STOCK Act.

This isn't the first time the Congressman has been active in the markets lately. Throughout 2026, Gottheimer has filed several reports showing sales in other major companies, including Applied Materials and McDonald's. These filings provide a window into the trading activity of lawmakers, though they are reported after the fact and don't necessarily signal a change in the company's underlying health.

Abbott Laboratories Stock Performance

On Saturday, Abbott Laboratories shares were priced at $90.90. The stock has experienced a wide range over the past year, reaching as high as $132.03 and dipping to a low of $81.97. Currently, the company has a market value of roughly $181.14 billion. While it isn't trading at its peaks, the company maintains a steady presence in the medical device and diagnostic markets. Its current valuation puts the price-to-earnings ratio at about 33.8, though forward-looking estimates suggest a lower ratio of 17.3 based on expected future profits.

Recent Earnings and Growth

Abbott reported revenue of $46.58 billion in its most recent financial period, achieving a revenue growth rate of 0.13%. The company managed a net margin of 11.65% and a return on equity of 10.58%. These figures show how much profit the firm generates from its sales and its shareholders' investments. Investors are now looking toward October 21, 2026, when the company is scheduled to release its next set of quarterly results.

Dividend Income for Shareholders

For those holding the stock for income, Abbott Laboratories offers an annual dividend yield of 2.41%. The company currently uses about 78.7% of its profits to fund these payments to investors. This consistent payout is a common feature for established healthcare firms that generate steady cash flow from long-term product lines.

Analysts Set New Price Targets

Several investment firms have recently updated their outlook on Abbott. On October 16, 2026, TD Cowen reiterated its buy rating with a $135.00 price target. Earlier that month, Barclays started coverage with an overweight rating and a $120.00 target, while Rothschild & Co upgraded the stock to buy on October 2, 2026, raising its target to $127.00. Overall, 26 analysts cover the stock, resulting in a consensus strong buy recommendation and an average price target of $120.72.

A Global Healthcare Leader

Abbott Laboratories is a massive healthcare company that builds everything from baby formula to high-tech heart stents. It operates in four main areas: medical devices, diagnostic tools, nutritional products, and generic medicines. Because it sells such a wide variety of essential health products around the world, its stock is often watched as a indicator of the broader medical industry's health.

What's Ahead for Abbott Laboratories

While the sale by Congressman Gottheimer represents a relatively small dollar amount, it adds to the ongoing record of legislative trading activity. Investors will likely focus more on the upcoming October 21 earnings report to see if the company can maintain its growth margins. As with all congressional disclosures, these reports show past moves and may not reflect the lawmaker's current sentiment or entire portfolio.